+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Drugs In Development, 2021

  • PDF Icon

    Report

  • 191 Pages
  • August 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5438182
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

According to the recently published report 'Histone Deacetylase 1 - Drugs In Development, 2021'; Histone Deacetylase 1 (HDAC1 or EC 3. 5.1. 98) pipeline Target constitutes close to 39 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes.

Histone Deacetylase 1 (HDAC1 or EC 3. 5.1. 98) - Histone deacetylase 1 is an enzyme encoded by the HDAC1 gene. The protein encoded by this gene belongs to the histone deacetylase family and is a component of the histone deacetylase complex. It also interacts with retinoblastoma tumor-suppressor protein and this complex is a key element in the control of cell proliferation and differentiation. Together with metastasis-associated protein-2 MTA2, it deacetylates p53 and modulates its effect on cell growth and apoptosis. It plays an important role in transcriptional regulation, cell cycle progression and developmental events.

The report 'Histone Deacetylase 1 - Drugs In Development, 2021' outlays comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 3. 5.1. 98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3. 5.1. 98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 7, 1, 17 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Cardiovascular, Gastrointestinal, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Melanoma, Diffuse Large B-Cell Lymphoma, Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Follicular Lymphoma, Colorectal Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Mycosis Fungoides, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Triple-Negative Breast Cancer (TNBC), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Glioblastoma Multiforme (GBM), HER2- Breast Cancer, Liver Cancer, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Melanoma, Myelodysplastic Syndrome, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Small-Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Unspecified B-Cell Lymphomas, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Alzheimer's Disease, Anal Cancer, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Basal Cell Carcinoma (Basal Cell Epithelioma), Becker Muscular Dystrophy, Beta Thalassaemia, Bladder Cancer, Blood Cancer, Bone Disorders, Cervical Cancer, Charcot-Marie-Tooth Disease Type II, Chronic Lymphocytic Leukemia (CLL), CNS Lymphoma, Cognitive Disorders, Colon Cancer, Duchenne Muscular Dystrophy, Gallbladder Cancer, Gastrointestinal Tract Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hemoglobinopathies, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Ischemia Reperfusion Injury, Kidney Cancer (Renal Cell Cancer), Liver Fibrosis, Lung Adenocarcinoma, Lung Cancer, Lymphoma, Merkel Cell Carcinoma, Metastatic Breast Cancer, Multiple Sclerosis, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroblastoma, Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Ovarian Cancer, Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Prostate Cancer, Rectal Cancer, Recurrent Medulloblastoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Rhabdomyosarcoma, Sezary Syndrome, Sickle Cell Disease, Skin Cancer, Solid Tumor, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), T-Cell Lymphomas, Unspecified Cancer, Unspecified Central Nervous System Disorders, Ureter Cancer, Urethral Cancer and Vulvar Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (HDAC1 or EC 3. 5.1. 98)
  • The report reviews Histone Deacetylase 1 (HDAC1 or EC 3. 5.1. 98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The ,report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3. 5.1. 98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 1 (HDAC1 or EC 3. 5.1. 98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 1 (HDAC1 or EC 3. 5.1. 98) targeted therapeutics

Reasons to Buy


  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (HDAC1 or EC 3. 5.1. 98)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (HDAC1 or EC 3. 5.1. 98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

IntroductionHistone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - OverviewHistone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics DevelopmentHistone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics AssessmentHistone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Drug Profiles
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Dormant Products

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Discontinued ProductsHistone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Product Development MilestonesAppendix
List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by 4D Pharma Plc, 2021
  • Pipeline by 4SC AG, 2021
  • Pipeline by Bristol Myers Squibb Co, 2021
  • Pipeline by Chengdu Jinrui Foundation Biotechnology Co Ltd, 2021
  • Pipeline by Curis Inc, 2021
  • Pipeline by GNT Biotech and Medicals Corp, 2021
  • Pipeline by Italfarmaco SpA, 2021
  • Pipeline by Jubilant Therapeutics Inc, 2021
  • Pipeline by Medibiofarma SL, 2021
  • Pipeline by Medivir AB, 2021
  • Pipeline by MEI Pharma Inc, 2021
  • Pipeline by Merck & Co Inc, 2021
  • Pipeline by Mirati Therapeutics Inc, 2021
  • Pipeline by Neuroene Therapeutics LLC, 2021
  • Pipeline by Oceanyx Pharmaceuticals Inc, 2021
  • Pipeline by OnKure Inc, 2021
  • Pipeline by Regenacy Pharmaceuticals LLC, 2021
  • Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2021
  • Pipeline by Shuttle Pharmaceuticals Inc, 2021
  • Pipeline by Syndax Pharmaceuticals Inc, 2021
  • Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, 2021
  • Dormant Products, 2021
  • Discontinued Products, 2021

List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 4D Pharma Plc
  • 4SC AG
  • Bristol Myers Squibb Co
  • Chengdu Jinrui Foundation Biotechnology Co Ltd
  • Curis Inc
  • GNT Biotech and Medicals Corp
  • Italfarmaco SpA
  • Jubilant Therapeutics Inc
  • Medibiofarma SL
  • Medivir AB
  • MEI Pharma Inc
  • Merck & Co Inc
  • Mirati Therapeutics Inc
  • Neuroene Therapeutics LLC
  • Oceanyx Pharmaceuticals Inc
  • OnKure Inc
  • Regenacy Pharmaceuticals LLC
  • Shenzhen Chipscreen Biosciences Co Ltd
  • Shuttle Pharmaceuticals Inc
  • Syndax Pharmaceuticals Inc
  • Zhejiang Hisun Pharmaceutical Co Ltd